This is an old revision of this page, as edited by Beetstra (talk | contribs) at 13:42, 17 February 2012 (Saving copy of the {{drugbox}} taken from revid 472437985 of page Afamelanotide for the Chem/Drugbox validation project (updated: 'ChEMBL', 'CAS_number').). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 13:42, 17 February 2012 by Beetstra (talk | contribs) (Saving copy of the {{drugbox}} taken from revid 472437985 of page Afamelanotide for the Chem/Drugbox validation project (updated: 'ChEMBL', 'CAS_number').)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff)This page contains a copy of the infobox ({{drugbox}}) taken from revid 472437985 of page Afamelanotide with values updated to verified values. |
Clinical data | |
---|---|
Other names | Melanotan; Melanotan-1; Melanotan I; CUV1647; EPT1647; NDP-MSH; α-MSH cc4)Cc5ncnc5)CCC(=O)O)CCCC)CO)Cc6ccc(O)cc6)(NC(=O)C)CO |
Routes of administration | S.C.; I.M.; I.V.; subcutaneous implant; intranasal |
ATC code |
|
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Elimination half-life | 0.8-1.7 hours (48-102 minutes) |
Identifiers | |
IUPAC name
| |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C78H111N21O19 |
Molar mass | 1646.845 g/mol g·mol |
3D model (JSmol) | |
SMILES
| |
InChI
|
- Ugwu SO, Blanchard J, Dorr RT; et al. (1997). <259::AID-BDD20>3.0.CO;2-X "Skin pigmentation and pharmacokinetics of melanotan-I in humans". Biopharmaceutics & Drug Disposition. 18 (3): 259–69. doi:10.1002/(SICI)1099-081X(199704)18:3<259::AID-BDD20>3.0.CO;2-X. PMID 9113347.
{{cite journal}}
: Explicit use of et al. in:|author=
(help); Unknown parameter|month=
ignored (help)CS1 maint: multiple names: authors list (link)